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against injectable second-line drugs from Pakistan:
Analysis of multidrug-resistant and non-multidrug-
resistant tuberculosis strainsNumber of isolates per year (%)
2010 2011 2012 2013 2014 Jan–July
MTB 3325 3129 3000 3390 1867
MDR-TB 1266 1292 1347 1680 818
K resistance 75 (5.9) 65 (5) 64 (2.1) 79 (2.3) 60 (7.3)
AK resistance 59 (4.7) 53 (4.1) 54 (1.8) 70 (2.1) 48 (5.7)
CAP resistance 66 (5.2) 44 (3.4) 58 (1.9) 81 (2.4) 70 (8.5)
Non-MDR TB 2059 1837 1653 1710 1049
K resistance 1 9 7 6 2
AK resistance 0 7 5 4 1
CAP resistance 17 15 11 18 NT
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Background and objective: Pakistan is one of the high-tuberculosis (TB) burden countries
(HBCs) with a considerable proportion of multidrug-resistant TB (MDR-TB) strains. Recently,
high resistance to fluoroquinolone has been reported in both MDR and non-MDR-TB strains
from Pakistan. This study aims to evaluate trends of resistance inMycobacterium tuberculosis
(MTB) against injectable second-line drugs (2010–July 2014) from Aga Khan University Lab-
oratory, a technical partner of the Pakistan National TB Program and part of the WHO
Supra-national Laboratory Network for TB based in Karachi, Pakistan.
Methods: MTB strains were isolated using standard methods. Susceptibility testing was per-
formed using the agar proportion method with drug concentrations as recommended by
the Clinical Laboratory Institute Standards (CLSI). MTB H37Rv was used as a control with
each batch of susceptibility testing. MDR-TB was defined as resistance to both isoniazid
(0.2 lg/ml) and rifampicin (1.0 lg/ml).
Results: During the study period, 14,711 MTB strains were isolated. Of these, 43.5% were
MDR and 56.5% were non-MDR. Resistance pattern to amikacin, kanamycin and capreomy-
cin over the years is shown in the table below.Total
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mycin; CAP: capreomycin; NT: not tested.
Conclusions: Rising resistance to injectable anti-tuberculous agents in MDR-TB isolates pos-
sibly reflects their increasing use in patient management. Presence of capreomycin resis-
tance even amongst non-MDR strains is alarming for a country where fluoroquinolone
resistance is also high and patient follow-up and drug compliance is a challenge.
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